|
| Press Releases |
|
 |
|
| Saturday, November 30, 2024 |
|
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Graid Technology Unveils SupremeRAID(TM) AE: The AI Edition Designed for GPU-Driven AI Workloads
Jan 8, 2025 13:00 HKT/SGT
|
|
|
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 8, 2025 12:30 JST
|
|
|
The Quantum Revolution. How Quantum Computing Will Transform the Global Economy in the Next Decade 
Jan 8, 2025 08:30 HKT/SGT
|
|
|
Stableton Partners with Alta to Expand Access to Global High-Growth Pre-IPO Investments
Jan 8, 2025 00:02 HKT/SGT
|
|
|
Asian Financial Forum held next week as the region's first major international financial assembly of 2025
Jan 7, 2025 22:33 HKT/SGT
|
|
|
Mitsubishi Motors to Display Custom Versions of the Triton at Tokyo Auto Salon 2025
Jan 7, 2025 15:41 JST
|
|
|
CleverTap Predicts Key Trends for Customer Engagement in 2025
Jan 7, 2025 14:30 HKT/SGT
|
|
|
'Toyota Woven City,' a Test Course for Mobility, Completes Phase 1 Construction and Prepares for Launch
Jan 7, 2025 15:25 JST
|
|
|
$INDX Token Pre-Sale Kicks Off as CryptoIndex.com Paves the Way for Decentralized Indexing
Jan 7, 2025 12:00 HKT/SGT
|
|
|
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Jan 7, 2025 9:14 JST
|
|
|
Spectral Achieves Major Patent Milestone Related to Quantum Computing
Jan 6, 2025 22:37 HKT/SGT
|
|
|
2025 Toys & Games Fair, Baby Products Fair, Stationery & School Supplies Fair open today
Jan 6, 2025 18:36 HKT/SGT
|
|
|
Toyota to Share Progress on Woven City at CES 2025
Jan 6, 2025 15:49 JST
|
|
|
Mazda to build Module Pack Plant for Cylindrical Lithium-ion Batteries for Automotive Use in Iwakuni City, Yamaguchi Prefecture
Jan 6, 2025 15:36 JST
|
|
|
AI Connect to Launch Revolutionary AI Agent, Redefining Financial and Technological Innovation
Jan 6, 2025 14:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
